Fennec Pharmaceuticals (FENC) Common Equity: 2011-2025
Historic Common Equity for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$4.5 million.
- Fennec Pharmaceuticals' Common Equity rose 13.13% to -$4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 million, marking a year-over-year increase of 13.13%. This contributed to the annual value of -$5.9 million for FY2024, which is 49.48% up from last year.
- As of Q3 2025, Fennec Pharmaceuticals' Common Equity stood at -$4.5 million, which was up 39.81% from -$7.5 million recorded in Q2 2025.
- Fennec Pharmaceuticals' Common Equity's 5-year high stood at $24.9 million during Q1 2021, with a 5-year trough of -$11.6 million in Q4 2023.
- Its 3-year average for Common Equity is -$4.2 million, with a median of -$5.9 million in 2024.
- In the last 5 years, Fennec Pharmaceuticals' Common Equity skyrocketed by 241.93% in 2023 and then slumped by 449.96% in 2025.
- Fennec Pharmaceuticals' Common Equity (Quarterly) stood at $19.0 million in 2021, then tumbled by 85.26% to -$2.6 million in 2022, then crashed by 352.39% to -$11.6 million in 2023, then soared by 49.48% to -$5.9 million in 2024, then rose by 13.13% to -$4.5 million in 2025.
- Its last three reported values are -$4.5 million in Q3 2025, -$7.5 million for Q2 2025, and -$5.9 million during Q1 2025.